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Abstract 
GOLPH2 is coding the 73kDa type II Golgi membrane antigen GOLPH2/GP73. Up-
regulation of GOLPH2 mRNA has been recently reported in expression array analyses of 
prostate cancer. Because GOLPH2 protein expression in prostate tissues is currently 
unknown, this study aimed at a comprehensive analysis of GOLPH2 protein in benign 
and malignant prostate lesions. 
Immunohistochemically detected GOLPH2 protein expression was compared with the 
basal cell marker p63 and the prostate cancer marker alpha-methylacyl-CoA racemase 
(AMACR) in 614 radical prostatectomy specimens.  
GOLPH2 exhibited a perinuclear Golgi type staining pattern and was preferentially seen 
in prostatic gland epithelia. Using a semiquantitative staining intensity score, GOLPH2 
expression was significantly higher in prostate cancer glands compared to normal glands 
(p<0.001). GOLPH2 protein was up-regulated in 567/614 tumours (92.3%) and AMACR 
in 583/614 tumours (95%) (correlation coefficient 0.113, p=0.005). Importantly, 
GOLPH2 immunohistochemistry exhibited a lower level of intratumoural heterogeneity 
(25% vs. 45%). Further, GOLPH2 upregulation was detected in 26 of 31 (84%) of 
AMACR-negative prostate cancer cases. 
These data clearly suggest GOLPH2 as an additional ancillary positive marker for tissue 
based diagnosis of prostate cancer. 
 
Keywords: GOLPH2, prostate cancer, diagnostic marker, immunohistochemistry 
 2
  
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
1. Introduction 
The identification of sensitive and specific biomarkers and tissue and serum is of utmost 
importance to reduce the mortality of prostate cancer (Parekh et al., 2007). Expression 
arrays, SNP analyses and mass spectrometry are novel tools for biomarker identification 
(Zheng et al., 2007). Such high throughput analyses have recently identified novel 
prostate cancer biomarkers, including e.g. HEPSIN, EZH2 and alpha-metyl-Co-racemase 
(AMACR) (Dhanasekaran et al., 2001; Jiang et al., 2001; Luo et al., 2001; Magee et al., 
2001; Parekh et al., 2007; Rhodes et al., 2003; Stamey et al., 2001; Varambally et al., 
2002). AMACR has first been found up-regulated in prostate cancer by Xu et al. using 
suppressive subtractive hybridisation and AMACR antibodies have quickly thereafter 
become available (Jiang et al., 2001; Rubin et al., 2002; Xu et al., 2000). So far, it is the 
only novel tissue biomarker of prostate cancer that has gained clinical acceptance. 
AMACR is frequently used in combination with the basal cell markers p63, CK5/6 and 
34betaE12. In diagnostic histopathology, absence of these basal cells which usually line 
the periphery of normal prostate glands is (with very rare exceptions) a defining criterion 
of invasive tumour growth (Brawer et al., 1985; Kaleem et al., 1998; Signoretti et al., 
2000). However, it can be difficult to ascertain a cancer diagnosis in prostate needle 
biopsies. Use of an additional positive prostate cancer marker is desirable. AMACR 
immunohistochemistry can show dramatic pictures of strongly positive cancer glands 
infiltrating perfectly negative benign prostatic parenchyma and in these cases its use 
may turn a diagnosis of atypical glands into a straightforward diagnosis of cancer 
(Epstein, 2004; Epstein & Herawi, 2006; Zhou et al., 2004; Zhou et al., 2003). However, 
it has been recognized that AMACR may be false negative in up to 18 percent of 
prostate cancer foci on biopsies and even higher in some carcinoma subtypes (Epstein, 
2004; Zhou et al., 2004). 
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Recently, GOLPH2 mRNA expression has been reported up-regulated in prostate cancer 
tissues (Kristiansen et al., 2005; Lapointe et al., 2004; Luo et al., 2002). GOLPH2 is a 
Golgi phosphoprotein of yet unknown function that has until very recently only been 
described in liver disease as a potential serum marker of hepatocellular carcinoma 
(Bachert et al., 2007; Iftikhar et al., 2004; Kladney et al., 2000; Kladney et al., 2002a; 
Marrero et al., 2005). GOLPH2 mRNA has recently been described as an integral part of 
a multiplex marker to detect prostate cancer from urine samples which even 
outperformed a PSA blood test (Laxman et al., 2008). 
In this study, we performed a comprehensive GOLPH2 protein expression analysis in a 
broad spectrum of normal and malignant tissues. Further, GOLPH2 expression patterns 
were studied in detail in different prostatic lesions. We demonstrate that GOLPH2 
protein is up-regulated in most prostate cancer cases. In addition to AMACR and p63, 
GOLPH2 antibodies will be helpful in correct histological prostate cancer diagnosis. 
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2.1. Data mining of publicly available prostate cancer mRNA expression data 
We interrogated the common gene expression databases Oncomine and Arrayexpress 
for differential expression of GOLPH2 mRNA in human prostate cancer and normal 
tissue(Parkinson et al., 2007; Rhodes et al., 2004). We identified nine studies within 
Oncomine (Dhanasekaran et al., 2001; Dhanasekaran et al., 2005; Lapointe et al., 2004; 
Luo et al., 2001; Luo et al., 2002; Nanni et al., 2006; Tomlins et al., 2007; Vanaja et al., 
2003; Varambally et al., 2005) and one study within Arrayexpress (Liu et al., 2006). 
Altogether, these studies interrogated 305 samples of prostate cancer in combination 
with 148 of benign prostate tissues. From the Oncomine database the normalized 
expression values for the nine studies were extracted and analyzed using SPSS. 
 
2.2. Prostate cancer patients 
Six-hundred-fourteen prostate cancer patients who underwent radical prostatectomy 
between 1999 and 2005 were enclosed in this study. Patient age ranged between 43 
and 74 years (median 62). Pre-operative PSA levels ranged from 0.8 to 39 ng/ml (median 
7.2). 44 patients (7.2%) had received gonadotropin-releasing hormone analogues at the 
discretion of the referring urologist prior to surgery (median 4 weeks, range 2 – 16 
weeks). Clinical follow-up data were annually assessed. PSA relapse free survival time 
was available for 479 patients. The median follow-up time of all cases was 17 months 
(range 1 – 68 months). The median follow-up time of patients without a PSA relapse 
was 18 months (range 4 – 68 months). 43 patients (9%) experienced a PSA relapse after 
a median time of 5 months (range 1 - 52). The Gleason scores (GS) in the cohort were 
distributed as follows: GS 2-6: 217 (35.3%) GS 7: 291 (47.4%), GS 8-10: 106 (17.3%). 
Four-hundred-twenty cases had organ confined carcinomas (pT2), 191 cases showed 
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extracapsular tumour extension (pT3). The surgical margins were clear (R0) in 444 cases, 
167 cases had positive margins (R1), 3 cases were Rx. Use this tissue has been approved 
by the Charite´ University Ethics Committee under the title ‘Retrospektive Untersuchung 
von Gewebeproben mittels immunhistochemischer Färbung und molekularbiologischer 
Methoden’ (‘Retrospective analysis of tissue samples by immunohistochemistry and 
molecular biological techniques’) (EA1/06/2004) on 20 September 2004. 
 
2.3. Screening Tissue Microarray construction 
Formalin fixed paraffin embedded material of a representative variety (185 spots) of 
normal and malignant human tissues and tumour cell lines were compiled and 
assembled on a single block, as described (Varga et al., 2006).  
 
2.4. Prostate Tissue Microarray construction 
Formalin fixed, paraffin embedded tissue blocks of radical prostatectomy specimens 
were selected according to tissue availability for construction of a TMA. Each case was 
represented by 5 tissue cores. In all cases, benign prostatic hyperplasia (BPH) or the 
transitional zone, normal tissue from the peripheral zone, prostatic intraepithelial 
neoplasia (PIN), if present (otherwise another core from the peripheral zone), and two 
cores of invasive carcinoma, ideally of primary and secondary Gleason score, were 
selected for TMA construction. The core diameter was 1.0 mm. All cases were arranged 
in 40 TMA recipient paraffin blocks. 
 
2.5. Immunohistochemistry 
The TMA blocks were freshly cut (3μm) and mounted on superfrost slides (Menzel 
Gläser). Immunohistochemistry was conducted with the Ventana Benchmark automated 
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staining system (Ventana Medical Systems, Tucson, AZ) using Ventana reagents for the 
entire procedure. To detect GOLPH2, two commercially available antibodies (mouse 
monoclonal, clone 5B10, Abnova Corporation, Taipei, Taiwan, catalog number 
H00051280-M06, dilution 1:1000 and rabbit polyclonal, Abcam, Cambridge, UK, 
catalog number Ab22209, dilution 1:100) were diluted in a Ventana diluent. To detect 
racemase and p63, we created a cocktail of racemase (rabbit polyclonal, Biologo, 
Kronshagen, Germany, dilution 1:30) and p63 (clone mix 4A4/Y4A3, Neomarkers, 
dilution 1:200) in a Ventana diluent. Primary antibodies were detected using the 
UltraVIEW DAB detection kit using the benchmarks CC1m- heat induced epitope 
retrieval. For the racemase/p63 cocktail the signal was further enhanced with the 
amplification kit. Slides were counterstained with hematoxylin, dehydrated and 
mounted. 
 
2.6. Evaluation of the immunohistochemical stainings 
Chromogenic immunohistochemistry using both GOLPH2 antibodies was primarily 
conducted on a multi-tissue array constructed for antibody testing comprising 185 
human tissue spots and cell lines. The immunostainings were evaluated by two 
genitourinary pathologists (GK, FFR) and one histopathology resident (CJ) simultaneously 
on a multiheaded microscope. 
For both GOLPH2 and Racemase we evaluated staining intensity with a four-tired 
system: 0 (negative), 1+ (weak), 2++ (moderate), 3+++ (strong) in benign tissue, PIN and 
invasive carcinoma. To detect also very subtle staining intensity differences, we further 
created a dichotomous (“tumour>normal”) ratio to better indicate upregulation in 
tumour in comparison to adjacent normal tissue. Equal or less GOLPH2 staining intensity 
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in carcinomatous tissue was reported as ratio 0, higher staining intensities than in 
normal glands were regarded as ratio 1. 
Heterogeneity of marker expression in invasive carcinoma was also recorded and 
diagnosed if more than 25% of the tumour showed a variation of staining intensity 
exceeding one scoring category. P63-immunoreactivity of the racemase/p63-cocktail 
was sometimes used to clearly distinguish benign and malignant glands. 
 
2.7. Monoclonal and polyclonal GOLPH2 doublestaining by immunofluorescence  
GOLPH2 is a Golgi potein. To better assess the specificity of the polyclonal and the 
monoclonal antibody, a double staining by immunofluorescence was conducted. Primary 
antibodies (mouse-anti GOLPH2, Abnova Corp., 1:4000; rabbit-anti GOLPH2, Abcam 
Ltd., 1:200) were co-incubated on a de-paraffinized prostate tissue slide after heat 
induced antigen retrieval (5 minutes, citrate buffer, pH6.0, 110°C) at room temperature 
for 30 minutes. Binding was detected by fluorescence labelled secondary antibodies 
(goat anti-rabbit-Alexa546 and goat anti-mouse-Alexa488, both from Molecular probes, 
catalog numbers A11010 and A11029) under a fluorescence microscope. 
 
2.8. Antibody preincubation with immunogenic peptide 
To further assess antibody specificity, the monoclonal antibody was incubated with an 
excess of the immunogenic peptide provided by the antibody supplier (partial 
recombinant protein (NP_057632, 302 a.a. - 402 a.a.) with GST, Abnova Corp., Taipeh, 
Taiwan) at 4°C overnight prior to application to the control tissue (Figure 2F). 
 
 8
  
190 
191 
192 
2.9. Statistical analysis 
Statistical analysis was performed using SPSS, version 15.0. P values < 0.05 were 
considered significant. 
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3. Results 
3.1. GOLPH2 mRNA expression in prostate cancer 
We reported previously that GOLPH2 mRNA is overexpressed in microdissected prostate 
cancer epithelium compared to the adjacent normal prostate epithelium from the same 
patient by a fold change of 2.2 (Kristiansen et al., 2005). Liu et al. described GOLPH2 
mRNA as overexpressed by a fold change of 3.14 in their samples (13 normal; 45 
cancer), which did not correlate to tumour differentiation according to Gleason scores 
(Liu et al., 2006). A comprehensive analysis of the studies from Oncomine combining 
260 samples from CaP and 135 from benign prostate normal revealed an overexpression 
of GOLPH2 by a factor of 2.7 in prostate cancer (p<0.001, Figure 1A). 
 
3.2. GOLPH2 protein expression in normal and neoplastic human tissue 
Both GOLPH2 antibodies showed identical stainings on a multi-tissue array comprising 
185 tissue spots and cell lines (Figure 2A/B). Highest rates of GOLPH2 expression were 
seen in adenocarcinomas of the prostate, colon and breast, but also in renal cell cancer 
and hepatocellular carcinoma (Table 1). Prostate cancer showed the strongest staining. 
GOLPH2 expression can be observed in mesenchymal cells and epithelia, but with 
strongly differing intensities. As can be expected from a Golgi-associated protein, it 
shows a distinct semi granular dot-like staining pattern, and is localized perinuclear 
towards the cells apex in epithelia, whereas the rest of the cytoplasm is remarkably clear 
(Fig. 2A&B, Fig. 3-5). To further cross-validate antibody specificity, a double 
immunofluorescent staining using both antibodies was conducted and demonstrated a 
clear co-localisation of the antigens in the Golgi apparatus (Figure 2C-E). Again, the 
mono- and the polyclonal antibody showed identical staining localisations. The 
monoclonal antibody was preferred for further immunostaining our prostate cancer 
 10
  
218 
219 
220 
221 
222 
223 
224 
225 
226 
227 
228 
229 
230 
231 
232 
233 
234 
235 
236 
237 
238 
cohort since it yielded slightly less background and a more intense signal at lower 
concentrations. Also, the pre-incubation of the monoclonal antibody with an excess of 
recombinant GOLPH2 protein completely abolished immunoreactivity (Figure 2F). 
 
3.3. GOLPH2 immunostaining in prostate tissues 
Perinuclear GOLPH2 expression is present in normal and neoplastic prostate glands with 
unequivocal upregulation in most hyperplastic and neoplastic glands in comparison to 
normal glands. Some cases of PIN and carcinoma, however, display an attenuation of 
the Golgi staining and an additional diffuse strong cytoplasmic immunoreactivity which 
was seen in 68 cases (11.1%) (Figures 3C, F). 
Normal prostatic glands show finely granular GOLPH2 staining, in some instances with 
an almost linear pattern (Figure 3A). The staining intensity is relatively weak yielding a 
more golden than brownish DAB precipitate. The median GOLPH2 intensity in normal 
tissue was 1+ (Figure 1B). Hyperplastic glands of benign prostatic hyperplasia show a 
moderate to strong staining intensity (Figure 3B). Glands with slightly atypical epithelia 
also show a stronger immunoreactivity than normal glands. This becomes even more 
pronounced in high grade PIN (median intensity 2+) and invasive carcinoma (median 
intensity 3+) wherein the granules are much coarser and stain deeply brown which 
yields a well discernable contrast to adjacent benign glands (Figures 3C-G, 5C,F). The 
statistical differences between GOLPH2 expression in normal, PIN and carcinoma was 
highly significant (Figure 1B; Wilcoxon signed rank test, p<0.001). 
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3.4. GOLPH2, histopathology and survival 
GOLPH2 protein expression in prostate cancer was not associated with pT stage, 
differentiation grade (Gleason score) and preoperative PSA levels. There was no 
association with disease free survival (Cox regression, relative risk 0.969, p=0.910). 
 
3.5. GOLPH2 as a potential tool for prostate cancer diagnosis 
The most impressive finding of this expression analysis was a striking difference in 
GOLPH2 expression in normal and neoplastic prostate glands. In 237 cases (38.6%) 
GOLPH2 intensity was 2 scoring points higher in tumour epithelia than in normal glands, 
in another 324 cases (52.8%) tumoural GOLPH2 expression excelled by 1 scoring point, 
in 51 cases (8.3%) no differences between normal and tumour were noted and in only 
two cases (0.3%) normal tissue showed a stronger GOLPH2 staining than adjacent 
tumour. In summary, 91.4% of cases showed an upregulation of GOLPH2 in the tumour 
by at least 1 scoring point. This rate is even higher in the separately scored 
“tumour>normal” ratio. This is able to measure even subtle differences: 567/614 cases 
(92.3%) had a ratio of 1, only 47 cases (7.7%) had a ratio of 0. 
To characterize GOLPH2 as a novel diagnostic tissue marker of prostate cancer, we 
conducted a careful comparison to the well established AMACR immunohistochemistry. 
As expected, AMACR was found overexpressed in high grade PIN (median score 1+) and 
invasive prostate cancer (median score 2+), whereas normal tissues were found negative 
(median score 0) (Figure 1B). AMACR overexpression in the tumour in direct comparison 
to adjacent normal tissue (“tumour>normal” ratio) was seen in 95% of cases. AMACR 
expression was significantly but not highly correlated to GOLPH2 expression (Table. 2, 
Spearman rank correlation coefficient 0.113, p=0.005). However, both markers also 
showed remarkable differences, particularly, when the tumour/normal ratio of GOLPH2 
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and AMACR were considered. Here, twenty-six of 31 AMACR negative cases (84%) 
were identified by GOLPH2. On the other hand, 42 of 47 cases (89%) without GOLPH2 
up regulation were AMACR positive. Five cases were concordantly negative, 541 cases 
were positive for both markers (Table 3). Four of the five cases negative for both 
markers were of higher Gleason scores. Examples of the comparison of AMACR and 
GOLPH2 expression in prostate tissues are shown in Figures 4 and 5. 
The histologically evident intratumoural heterogeneity of prostate cancer is also reflected 
in biomarker expression. In this study, intratumoural AMACR and GOLPH2 
heterogeneity of expression was also evaluated. AMACR has a considerably higher 
degree of heterogeneous expression (45% of cases) than GOLPH2 (25%). This 
heterogeneity (Figure 4E) can be troublesome in small tumour foci. In forty-three cases 
one of two TMA tumour cores was completely AMACR negative, whereas the other 
core of the same case showed some immunoreactivity. Of these AMACR negative cores, 
GOLPH2 was up-regulated in 36 cases (84%). 
The combination of GOLPH2 and AMACR showed expression of either marker in 99.2% 
of cancer cases, which advocates a combined use of AMACR and GOLPH2 as positive 
confirmative markers of prostate cancer. 
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4. Discussion 
This is the first report on GOLPH2 (Golgi Protein 73, GP73) protein expression in 
prostate tissues validated on a large cohort of clinically detected prostate cancer 
specimens following radical prostatectomy. We have recently shown that GOLPH2 
mRNA is among the top up-regulated transcripts in prostate cancer (Kristiansen et al., 
2005), which is in line with other profiling studies (Dhanasekaran et al., 2001; 
Dhanasekaran et al., 2005; Lapointe et al., 2004; Liu et al., 2006; Luo et al., 2001; Luo 
et al., 2002; Nanni et al., 2006; Tomlins et al., 2007; Vanaja et al., 2003; Varambally et 
al., 2005). In our meta-analysis of publicly available expression data encompassing 260 
prostate cancer cases, a mean change fold of 2.7 for GOLPH2 upregulation in cancerous 
tissues was found. However, a detailed tissue based in situ analysis of GOLPH2 protein 
in prostate tissues was lacking so far. Very recently, this widely acknowledged 
upregulation of GOLPH2 was put into practise: Laxman et al. included GOLPH2 in a 
multiplex RT-PCR panel of markers composed of transcripts known to be overexpressed 
in prostate cancer, which, as a urine based screening test, allows detecting prostate 
cancer with a higher sensitivity than a classical PSA blood test (Laxman et al., 2008). 
GOLPH2 is a 73kDa Golgi apparatus associated protein coded by the gene GOLM1 
located on chromosome 9q21.33 and was originally cloned from a library derived from 
liver tissue of a patient with adult giant-cell hepatitis (Kladney et al., 2000). The initial 
report also described GOLPH2 expression in a variety of other human tissues on RNA 
and protein level and demonstrated colocalization of GOLPH2 with giantin, a type II 
Golgi membrane protein, located at the cis – and medial-Golgi compartment. 
Structurally, GOLPH2 protein consists of a short cytoplasmic N-terminus, a membrane-
spanning region, some coiled-coil domains and a longer luminal C-terminus with several 
potential glycosylation sites. The functions and the mechanisms of GOLPH2 regulation in 
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normal and neoplastic tissues are still unclear. It can be generally assumed, that it is 
either involved in posttranslational protein modification, transport of secretory proteins, 
cell signalling regulation or simply maintenance of Golgi apparatus function. Functional 
assays are necessary to clarify, if GOLPH2 overexpression confers pro-tumourigenic 
properties to tumour cells and how it is regulated. First colocalization experiments with 
GPP130, another Golgi marker, hinted at a differential colocalization between with 
GOLPH2 in normal and malignant prostate tissues, which deserves further study. 
GOLPH2 has several potential glycosylation sites and up to 75% of GOLPH2 secreted 
from hepatocytes is fucosylated, but so far the glycosylation patterns of GOLPH2 in 
malignant and normal prostatic epithelia have not been analysed (Norton et al., 2007). 
In the liver cancer cell line HepG2 GOLPH2 was found strongly up-regulated after 
adenoviral infection, which suggested GOLPH2 as a marker of viral infection in liver 
tissue and which was confirmed in following studies incorporating clinical samples 
(Kladney et al., 2002a; Kladney et al., 2002b). More recently, GOLPH2 was found up-
regulated in serum of patients with hepatocellular carcinoma (HCC) compared to 
healthy individuals and has been proposed as a novel serum marker of HCC, which is 
more sensitive than alpha-fetoprotein (Block et al., 2005; Marrero et al., 2005). 
Apparently, GOLPH2 overexpressing hepatocytes secrete this normally membrane bound 
Golgi protein after cleavage into the serum which can be diagnostically utilized (Bachert 
et al., 2007). We can confirm the GOLPH2 expression in HCC, however, the finding that 
adenocarcinomas of the colo-rectum, the breast and the prostate showed equally strong 
or even stronger immunostainings, argues against GOLPH2/GP73 as a HCC specific 
tissue marker. This finding also implies, that further serum analysis of non-HCC cancer 
patients, especially prostate cancer patients, are clearly necessary, before the role of 
GOLPH2/GP73 as a serum marker specific of HCC can be further established. 
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The histological diagnosis of prostate cancer mainly rests on the conventional 
parameters of morphological architecture and cytology. PSA serum screening has led to 
an increase of prostate needle biopsies in the last two decades, which in turn increased 
the rate of difficult diagnostic situations (small carcinoma infiltrates vs. benign mimickers 
of carcinoma) where immunohistochemical tests are necessary. Loss of basal cells is a 
hallmark of prostate cancer hence high molecular weight cytokeratins (HMWCK) and 
p63 have become widely used basal cell tissue markers. However, even with a loss of 
basal cells, cancer diagnosis can be problematic in some cases. Additional markers of 
prostate cancer are desirable. So far only AMACR/racemase has gained wider 
acceptance as a positive marker of prostate cancer, although is has two well known 
limitations: intratumoural heterogeneity, which was confirmed in 45% of our cases, and 
AMACR negative carcinomas (Murphy et al., 2007; Wang et al., 2006). In our series, 31 
completely AMACR negative carcinomas (5%) and another 43 cases (7%) in which one 
of both tumour cores on the TMA was negative, were seen. In these 12% of cases, 
which might have been considered negative on a needle biopsy an additional GOLPH2 
immunostaining would have allowed a cancer diagnosis in 84% of cases. This is partially 
due to the considerably lower rate of intratumoural heterogeneity of GOLPH2, which 
was 25% in our series. These findings clearly advocate the use of GOLPH2 as an 
additional ancillary positive marker for the histological detection of prostate cancer. 
Comparable to the introduction of AMACR we would expect that the number of 
unclear cases can be further lowered by GOLPH2, which would help to avoid costly and 
unnecessary re-biopsies (Jiang et al., 2004). Although a GOLPH2 immunostaining is not 
as easy to read as an AMACR staining at first sight, mainly because of the physiological 
basal GOLPH2 expression in normal tissues, we think that the internal positive control of 
immunoreactivity in normal tissues can also be seen as an advantage. Also, the 
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characteristic Golgi pattern is another indicator of specific immunoreactivity, whereas a 
general overstaining of a slide is often more diffusely cytoplasmic. 
In spite of our comprehensive description of GOLPH2 as a positive marker of 
malignancy, we would hesitate to recommend using GOLPH2 as the primary second-line 
antibody after basal cell markers for determining malignancy. First, its sensitivity is 
slightly lower (92.3%) than AMACR (95.0%), which is of course compensated for by its 
higher homogeneity. Secondly and more importantly, definition of a positive test result 
requires adjacent normal glands for direct comparison, since high grade PIN and 
hyperplastic benign glands can also show GOLPH2 upregulation. It can be difficult or 
even impossible to diagnose an atypical focus which lacks adjacent normal glands by 
GOLPH2 immunohistochemistry alone. The comparison to normal tissue is mandatory to 
obtain a valid result. Another caveat stems from the construction of our TMA, which has 
been compiled after central review of 640 fully embedded prostatectomy specimens in 
order to allow an immunohistochemical evaluation of representative normal and tumour 
tissue. Benign cancer mimickers, which can be particularly problematic to diagnose on 
needle biopsies, were not intentionally sampled. Further validation of the diagnostic 
value of GOLPH2 in rare cancer variants and benign cancer mimickers is necessary. 
 
In summary, this study is the first to confirm on protein level the GOLPH2 up-regulation 
in prostate cancer which has been suggested in preceding mRNA profiling studies. The 
high rate of GOLPH2 protein overexpression which is also seen in AMACR-negative 
prostate cancer cases suggests its use as an additional ancillary positive tissue marker of 
prostate cancer. 
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Table 1 GOLPH2 expression in normal and neoplastic human tissues and cell lines 
 
 
Tissue/cell line (n) GOLPH2 
negative 
GOLPH2 + GOLPH2 
++ 
GOLPH2 
+++ 
Normal testis (2) 0 2 0 0 
Seminoma (2) 0 1 1 0 
Teratoma (2) 0 1 1 0 
Placenta (2) 0 2 0 0 
Invasive lobular breast carcinoma (4) 0 0 3 1 
Invasive ductal breast cancer (4) 0 1 2 1 
Cholangiocarcinoma (2) 0 0 1 1 
Hepatocellular carcinoma (HCC) (2) 0 0 1 1 
lung Adenocarcinoma (1) 0 0 1 0 
lung squamous cell carcinoma (1) 1 0 0 0 
lung small cell carcinoma (1) 0 1 0 0 
Serous ovarian carcinoma (2) 1 1 0 0 
Ovarian endometrioid carcinoma (1) 0 0 1 0 
Ovarian mucinous carcinoma (1) 0 0 1 0 
Endometrium endometrioid carcinoma (2) 0 1 0 1 
Endometrium serous carcinoma (2) 0 1 1 0 
Colon adenocarcinoma (4) 0 1 1 2 
GIST (1) 0 0 1 0 
Skin squamous cell carcinoma (2) 1 1 0 0 
Merkel cell carcinoma (1) 0 1 0 0 
Anaplastic oligodendroglioma (1) 0 1 0 0 
Anaplastic astrocytoma (1) 0 1 0 0 
Glioblastoma multiforme (1) 0 0 1 0 
Thyroid papillary carcinoma (2) 0 1 0 1 
Thyroid follicular carcinoma (1) 0 0 1 0 
Thyoid anaplastic carcinoma (1) 0 0 0 1 
Normal kidney (2) 0 2  0 0 
Clear cell renal cell carcinoma (4) 0 0 0 2 
papillary renal cell carcinoma (2) 0 0 0 2 
Urothelial carcinoma, bladder (4) 0 0 3 1 
Adenocarcinoma, prostate (4) 0 0 1 3 
Benign prostatic hyperplasia (2) 0 0 2 0 
Normal liver (2) 0 2 0 0 
Tonsils (3) 0 3 0 0 
Non-Hodgkin Lymphoma (4) 0 2 2 0 
Hodgkin Lymphoma (1) 1 0 0 0 
Melanoma (1) 0 1 0 0 
HA98 (2) (melanoma) 0 0 2 0 
HN2004 (2) (melanoma) 0 0 0 2 
PF2000 (2) (melanoma) 0 0 2 0 
MET5A (2) (mesothelioma) 0 0 2 0 
SW480 (2) (colon cancer) 0 2 0 0 
786-O (2) (renal cell cancer) 0 0 0 2 
H69 (2) (lung cancer) 0 0 2 0 
MCF-7 (2) (breast cancer) 0 0 2 0 
SK BR 7 (2) (breast cancer) 0 2 0 0 
HELA (2) (cervical cancer) 0 2 0 0 
PC3 (2) (prostate cancer) 0 2 0 0 
293-T (2) (human embryonal kidney) 0 2 0 0 
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388 Table 2 GOLPH2 protein expression in prostate cancer 
GOLPH2 Expression  
1+ 2+ 3+ p-value 
All cases  10 (1.6%) 275 (44.8%) 329 (53.6%)  
Age 
62 6 (1.9%) 143 (46.3%) 160 (51.8%) 
>62 4 (1.3%) 132 (43.3%) 169 (55.4%) 
0.321 
Pre-OP PSA* 0.475 
10ng/ml 5 (1.1%) 197 (44.6%) 240 (54.3%) 
>10ng/ml 5 (3.0%) 73 (44.2%) 87 (52.7%) 
 
pT-status 0.267 
pT2 8 (1.9%) 194 (45.9%) 221 (52.2%) 
pT3/4+ 2 (1.0%) 81 (42.4%) 108 (56.5%) 
 
Gleason sum 0.264 
3-6 1 (0.5%) 92 (42.4%) 124 (57.1%) 
7 7 (2.4%) 136 (46.7%) 148 (50.9%) 
8-10 2 (1.9%) 47 (44.3%) 57 (53.8%) 
 
Residual tumour** 0.457 
R0 6 (1.4%) 206 (46.4%) 232 (52.3%) 
R1 4 (2.4%) 68 (40.7%) 95 (56.9%) 
 
AMACR expression 0.005 
0 2 (10.5%) 7 (36.8%) 10 (52.6%) 
1+ 3 (3%) 53 (52.5%) 45 (44.6%) 
2+ 2 (0.6%) 152 (47.2%) 168 (52.2%) 
3+ 3 (1.7% 63 (36.6%) 106 (61.6%) 
 
389 
390 
391 
392 
393 
Abbreviations: Preoperative PSA = Pre-Op PSA, tumour stage = pT-status. 
* Preoperative PSA was not available for seven cases 
+ One case was pT4 
** Three cases were Rx 
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Table 3 Tumour/Normal ratio of AMACR and GOLPH2 expression in prostate cancer 
 
GOLPH2 tumour>normal  
No Yes 
Total 
AMACR 
No 5 26 31 (5%) AMACR 
tumour>normal Yes 42 541 583 (95%) 
Total GOLPH2 47 (7.7%) 567 (92.3%)  
396 
397 
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Figure Legends 
Figure 1. GOLPH2 Expression in prostate tissues on mRNA and protein level 
A Boxplot of the combined normalized expression values of the nine studies from 
Oncomine interrogating normal and cancerous prostate tissues. The fold changes and 
the respective p-values are indicated above the brackets. FC: fold change; N: normal 
prostate; CaP: prostate cancer tissue. The open circles indicate outliers. B Illustration of 
the progression of GOLPH2 (on the left) and AMACR expression (on the right) from 
normal tissue via PIN to invasive carcinoma (immunohistochemical data). 
 
Figure 2. Characterization of GOLPH2 antibodies 
A/B Chromogenic immunocytochemistry of the paraffin embedded melanoma cell line 
PF2000. Both antibodies (A - mouse monoclonal, Abnova, B – rabbit polyclonal, Abcam) 
show a strong semi-granular perinuclear staining which is suggestive of a Golgi pattern. 
C-D Immunofluorescent double staining of a prostate cancer gland using both GOLPH2 
antibodies (C – mouse monoclonal, D – rabbit polyclonal). The signal of both antibodies 
is clearly located to the golgi apparatus, which can now be appreciated by the higher 
resolution of immunofluorescence. Figure E demonstrates the colocalization of the 
immunoreactivity of both antibodies (plus DAPI staining) and it also shows that the 
polyclonal antibody (red signal) has a less favourable signal to background ratio. Figure 
F1 shows a GOLPH2 immunohistochemistry (monoclonal antibody) of prostate cancer 
tissue (lower part- malignant glands, upper part- normal glands), in Figure F2 a 
consecutive section of the same case was immunostained after pre-incubation of the 
antibody with an excess of the immunogenic GOLPH2 peptide, which abolishes 
immunoreactivity. 
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Figure 3. GOLPH2 expression in prostate tissues 
A Normal secretory epithelium of normal prostate glands (immunoreactivity score 1+). B 
Hyperplastic gland with stronger GOLPH2 expression (score 2+). C Transition of normal 
epithelium (arrowheads) to high grade PIN. Note prominent nucleoli (arrows). This PIN 
has a strong GOLPH2 immunoreactivity (3+) and shows an additional diffuse cytoplasmic 
staining. D Gleason 3+3=6 adenocarcinoma (central) infiltrating in between normal 
glands (marked “N”). Note the upregulation of GOLPH2 (3+) in comparison to normal 
glands. E Same case at a higher magnification. Note the characteristic Golgi pattern. F 
Gleason 3+3=6 adenocarcinoma, with a more diffuse cytoplasmic GOLPH2 staining 
(3+). Note neural invasion (lower left). G High grade adenocarcinoma (Gleason score 
3+4=7) with a strong and coarse GOLPH2 staining (3+). 
 
Figure 4. Comparison between AMACR/p63 and GOLPH2 immunohistochemistry 
A AMACR expression in invasive cancer glands. Epithelium of normal glands, with a 
p63-positive basal cell layer, is AMACR negative. B Sequential section showing GOLPH2 
up-regulation in matching cancer glands (score 2+), adjacent normal glands are weakly 
GOLPH2 positive (score 1+). C shows an AMACR-negative example of invasive prostate 
cancer, whereas the same tumour has a significant upregulation of GOLPH2 (D) in 
comparison to normal glands (upper left corner, lower right corner). The case depicted 
in E&F has no included normal glands, but nonetheless a very strong GOLPH2 
expression (3+), which is rarely seen in normal glands. 
 
Figure 5. Two examples (A-C, D-F) of prostate needle biopsies (H&E, 
AMACR/p63, GOLPH2) 
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A Prostate needle biopsy with a small focus of a Gleason 3+3 adenocarcinoma (arrow). 
Sequentials sections of this focus show a lack of p63-positive basal cells and a moderate 
AMACR-immunoreactivity (B). GOLPH2 is moderately-strongly expressed in these glands, 
compared to adjacent normal glands (arrowheads), which have a weaker GOLPH2 
staining (C).  
D Another example of a prostate needle biopsy with atypical glands, some are macro-
acinar (arrow), some (lower right) are smaller (*). E The AMACR/p63-coctail 
demonstrates a continuous basal cell layer in larger normal gland on top (marked “N”), 
the macroacinar glands directly adjacent to it and the microacinar proliferates in the 
lower right corner have no basal cells. In between is a larger gland with a disrupted 
basal cell layer, probably diagnostic of a high grade PIN. All these glands are strongly 
positive for AMACR and for GOLPH2 (F). It is of importance to note, that in this case 
both markers (AMACR, GOLPH2) do not differentiate between the high grade PIN and 
the invasive carcinoma. 
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